SCHEMBL1551186

SCHEMBL1551186

CCCCCOc1ccc(/C=C/C(=O)O)cc1

nearest known ligand 0.65

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.62
THRB P10828 1/20 0.58
ATM Q13315 1/20 0.58
TP53 P04637 1/20 0.58
TSHR P16473 1/20 0.58
POLB P06746 1/20 0.58
PLA2G4B P0C869 1/20 0.56
BCHE P06276 4/20 0.56
ACHE P22303 2/20 0.56
SAE1 Q9UBE0 1/20 0.54
UBA2 Q9UBT2 1/20 0.54
RARB P10826 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1942953 1.00 ABCG2 (0.62) ABCG2THRBATMTP53TSHR
SCHEMBL1051794 0.98 TP53 (0.60) ABCG2THRBATMTP53TSHR
SCHEMBL7242747 0.98 TP53 (0.60) ABCG2THRBATMTP53TSHR
SCHEMBL7273131 0.98 TP53 (0.60) ABCG2THRBATMTP53TSHR
SCHEMBL22438883 0.98 TP53 (0.60) ABCG2THRBATMTP53TSHR
SCHEMBL9650506 0.98 TP53 (0.60) ABCG2THRBATMTP53TSHR
SCHEMBL7273143 0.98 TP53 (0.60) ABCG2THRBATMTP53TSHR
SCHEMBL22438884 0.98 TP53 (0.60) ABCG2THRBATMTP53TSHR
SCHEMBL7044767 0.98 TP53 (0.60) ABCG2THRBATMTP53TSHR
SCHEMBL6361553 0.98 TP53 (0.60) ABCG2THRBATMTP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230139366-A1 BRARTEMICIN ANALOGUES VICTORIA LINK LIMITED (NZ) 2023-05-04 US disclosed
US-8747804-B2 Modified zinc oxide particles BASF SE (DE) 2014-06-10 US disclosed
EP-2313345-B1 MODIFIED ZINC OXIDE PARTICLES BASF SE (DE) 2013-03-06 EP disclosed
US-20110130273-A1 MODIFIED ZINC OXIDE PARTICLES BASF SE (DE) 2011-06-02 US disclosed
EP-2313345-A1 MODIFIED ZINC OXIDE PARTICLES BASF SE (DE) 2011-04-27 EP disclosed
WO-2010007039-A1 MODIFIED ZINC OXIDE PARTICLES BASF SE (DE) 2010-01-21 WO disclosed
WO-2009101016-A2 MODIFIED HYBRID NANOPARTICLES BASF SE (DE) 2009-08-20 WO disclosed
US-6277502-B1 ORGANOSILICON POLYMERS; LIQUID CRYSALS ROLIC AG (CH) 2001-08-21 US disclosed
US-4978523-A P-hydroxycinnamides to remove pigment deposits in skin KAO CORPORATION (JP) 1990-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139366-A1 BRARTEMICIN ANALOGUES RXFP1, RXFP2, RXFP4 ABCG2 4866/4885THRB 1320/4885ATM 4323/4885
US-20110130273-A1 MODIFIED ZINC OXIDE PARTICLES SOD1, LPO, SOD3 ABCG2 3328/4885THRB 3394/4885ATM 2945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.